Description: The IFRS 17 implementation deadline is near and companies have decisions to make. While many decisions pertain to specific IFRS 17 requirements, others are more strategic in nature. This session will explore key considerations and decisions faced by stakeholders as they finalize their implementation work and determine ongoing best practices in light of this new standard.

Description: Actuarial models and modeling processes continue to grow in complexity, accelerated by the changes in U.S. Statutory, U.S. GAAP and IFRS reporting requirements in the past few years. Modeling and valuation teams are expanding their toolkits beyond the traditional vendor-maintained actuarial software and the MS Office suite of tools. Companies have started to use a variety of tools to improve model dev and valuation processes, including: - Data management - Automation and workflow - Reporting and analytics

Description: Models are a staple of an insurance company's operations. However, models that are not appropriately governed may lead to underpriced products, under-funded reserves, unfairly treated customers, and potentially catastrophic operational, legal, and reputational risks. Model Risk Management (MRM), an essential component of an insurer's ERM function, needs to keep pace with the rapidly evolving model ecosystem to limit model risk and produce results that management can trust when employing company strategy. With the adoption of ASOP #56, emerging technologies, and regulatory changes such as PBR, LDTI and IFRS 17, it is increasingly important for MRM frameworks and processes to adapt, upgrade and evolve. Discuss insights on how to embed ASOP 56 into Model Risk Management (MRM) and assess the design, development, modifications, and validation of actuarial models, the advancement of analytics and technology that empower insurers for process optimization and automation, as well as the the key components, stakeholders, best practices, and strategic benefits of a comprehensive MRM framework. Go over use cases on enhancing MRM in the context of ASOP 56, technology, and model governance. Explore how automation and optimization of the MRM process will allow companies to realize the strategic benefits of MRM, ensure successful adoption of regulation changes, and the pros and cons of emerging technology on MRM. By attending the session, you will be able to: - Describe how ASOP 56 can help improve MRM processes. - Describe the key components, stakeholders, best practices, and strategic benefits of a comprehensive MRM framework. - Identify where and how to use technology to automate and optimize the MRM process. - Evaluate the impacts of emerging technology on MRM.

Description: With the mandated health plan transparency files, health plans and providers are now able to substantially enhance their provider contracting efforts. Although the files are large and cumbersome they are market disruptors and provide new insights for provider contracting efforts. Explore a demonstration on the type of information now available and how it can be used to enhance this from both a health plan and health care provider perspective.

Description: "Explore a general introduction to the opportunity of applying a relatively newer area in machine learning called uplift modeling, which has been successfully used in retail (Wayfair etc). The concepts are parallel to the intervention programs in health care, where we are interested in measuring the treatment effects and ultimately directing the right members to the most effective programs, driving the highest value for the programs both from a financial and health outcomes perspective. Uplift modeling can also be viewed in context of causal modeling where we are interested in assigning cause to a treatment relative to a member not receiving the treatment. Check out an introduction on the concept, seehow it relates and builds on existing work, and use a demo to showcase the potential of integrating this ML approach to current work."

Description: "Can you answer the question 'what are the chances we will lose more than $1 million next year?' without saying 'it depends'? If you miss a projection, can you quantify the chances that the miss was due to random variation vs. an incorrect projection? ten in as presenters demonstrate how to answer these questions and others using total risk analysis. Total risk analysis includes quantifying both the random variation risk and the projection risk associated with actuarial functions like pricing and reserving. After attending this session, you will be able to describe total risk analysis, apply total risk analysis to many actuarial functions."

Description: Actuaries historically modeled new launches in pharmaceuticals by anticipating the expected change to the market basket. This became more complicated with the recent launches of gene and cell therapies as they address rare diseases. Rare conditions have low total member volume to study and some do not currently have a diagnosis code to identify them within claims data. Addressing this modeling challenge has been growing more important in the recent years with the number of therapies launching. What has the health care industry, and more specifically health care, done to enhance modeling and how should this be altered for the future? Additionally, historic modeling has sometimes incorporated a level of direct medical treatment cost offsets where studies have shown lower treatment costs are achievable. Can gene and cell financial modeling include cost offsets as well? And if so, what are suggested precautions or limitations to this effort?

Description: "Hear AM Best rating analysts discuss the rating process and the best capital adequacy ratio (BCAR), a quantitative foundation for AM Best’s assessment of carriers’ financial strength. The benchmarking of BCAR scores for various company types (national MCOs, BCBS plans, smaller regional plans) will be discussed. Look at how changes in investment and underwriting environment impacted the results over the past several years. Further, AM Best’s view of the quality of capital and various factors impacting the overall assessment of the balance sheet strength will be discussed. By attending this session, you will: Gain an understanding of AM Best’s building block approach to ratings and how the BCAR results fit into the process. Learn the differences between RBC and BCAR models. Learn how various factors—e.g. liquidity, financial flexibility, financial leverage, the org structure—impact the final AM Best assessment of health companies' capital."